The researchers found that PI-RADS category > 3 assessments with the PI-RADS v2.1 system had patient-level sensitivity and specificity of 96 percent and 43 percent, respectively, for the detection of clinically significant prostate cancer<\/a> (csPCa). For patients with PI-RADS category > 3 evaluations, the PI-RADS v2.1 system offered respective patient-level sensitivity and specificity of 88 percent and 66 percent for csPCa, according to the meta-analysis authors.<\/p>\n Drawing on data from over 100 studies and over 25,000 patients, the authors of a new meta-analysis found robust sensitivity rates for PI-RADS category 3 and higher assessments with the PI-RADS v2.1 system for interpreting prostate magnetic resonance imaging (MRI).<\/p>\n The meta-analysis findings also revealed cancer detection rates (CDRs) of 83 percent for PI-RADS category 5, 53 percent for PI-RADS category 4, 20 percent for PI-RADS category 3, 6 percent for PI-RADS category 2 and 3 percent for PI-RADS category 1.<\/p>\n \u201cThe present data con\ufb01rm the available evidence regarding the (PI-RADS v2.1) system\u2019s high sensitivity and low CDRs of low PI-RADS categories,\u201d wrote meta-analysis lead author Andrea Nedelcu, M.D., who is affiliated with the Department of Radiology at the University of Freiburg Medical Center in Freiburg, Germany, and colleagues.<\/p>\n Employing the QUADRAS-2 tool for assessing the quality of the reviewed studies, the meta-analysis authors found that 34 of the studies had a high risk of bias or questionable applicability.<\/p>\n Three Key TakeawaysHigh sensitivity for csPCa detection. The PI-RADS v2.1 system demonstrated strong patient-level sensitivity (up to 96%) for identifying clinically significant prostate cancer, particularly in PI-RADS category \u22653 assessments.Strong correlation between PI-RADS category and cancer risk. Cancer detection rates rose progressively with higher PI-RADS categories \u2014ranging from 3 percent in PI-RADS 1 to 83 percent in PI-RADS 5 \u2014 supporting the system\u2019s effectiveness in stratifying malignancy risk.Quality of evidence impacts accuracy. Nearly one-third of included studies had a high risk of bias or concerns about applicability, underscoring the need for consistent, high-quality study designs in future PI-RADS v2.1 evaluations.<\/p>\n For studies deemed to have a high risk of bias, the researchers noted 11 percent lower lesion-level sensitivity in PI-RADS category > 4 assessments (78 percent vs. 89 percent) as well as an 11 percent higher CDR for PI-RADS category > 2 evaluations (15 percent vs. 4 percent) in contrast to studies without a high bias risk.<\/p>\n \u201c \u2026 A considerable proportion (29%) of studies had a high risk of bias and\/or high concerns of applicability. These high-risk studies were associated with signi\ufb01cantly reduced sensitivity and signi\ufb01cantly increased CDR for PI-RADS category 2 in certain estimates, suggesting potentially \ufb02awed estimates resulting from inclusion of investigations with quality issues,\u201d noted Nedelcu and colleagues.<\/p>\n (Editor\u2019s note: For related content, see \u201cIs PI-RADS Version 2.1 Outdated for Prostate MRI?<\/a>,\u201d \u201cMRI-Based Deep Learning Model Bolsters Prediction of PI-RADS 3 and 4 Lesions<\/a>\u201d and \u201cStudy: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast<\/a>.\u201d)<\/p>\n In regard to limitations of the meta-analysis, the authors acknowledged the lack of a uniform definition for csPCa in the reviewed studies, the lack of PI-RADS v2.1 assessment for those on active surveillance for known PCa and the exclusion of non-English language studies from the meta-analysis.<\/p>\n","protected":false},"excerpt":{"rendered":"A large meta-analysis involving over 100 studies and over 25,000 patients revealed robust sensitivity rates for PI-RADS category…\n","protected":false},"author":2,"featured_media":84747,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[54681,54680,14467,14468,103,61,60,14457,34579,34576,14455,14466,54679,54678,54675,54676,54677,54674,14465,14456,54682],"class_list":["post-84746","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-andrea-nedelcu","tag-cancer-detection-rate-cdr","tag-clinically-significant-prostate-cancer-cspca","tag-cspca","tag-health","tag-ie","tag-ireland","tag-magnetic-resonance-imaging","tag-md","tag-meta-analysis","tag-mri","tag-pca","tag-pi-rads-category-1","tag-pi-rads-category-2","tag-pi-rads-category-3","tag-pi-rads-category-4","tag-pi-rads-category-5","tag-pi-rads-v2-1-criteria","tag-prostate-cancer-pca","tag-prostate-mri","tag-university-of-freiburg-medical-center"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/84746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=84746"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/84746\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/84747"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=84746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=84746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=84746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2025\/10\/882bbfe9ef8db275ece002d52f89abb8cd171bf9-1200x900.jpg\"\/)
<\/p>\n